Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
NASDAQ Composite
Standard & Poors 500
My Portfolio
DataMeds AI, Inc. - Common Stock
(NQ:
MEDS
)
0.7343
+0.0940 (+14.68%)
Delayed Quote
Updated: 1:26 PM EST, Nov 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about DataMeds AI, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
How AI and Anticancer Peptides Could Reshape the Future of Cancer Treatment
Today 8:30 EST
EQNX::TICKER_START (NASDAQ:MEDS),(NASDAQ:NEO),(NASDAQ:ANT),(NASDAQ:RXRX),(NASDAQ:OBIO) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
How AI and Anticancer Peptides Could Reshape the Future of Cancer Treatment
Today 8:30 EST
Advanced AI Platforms Are Helping Researchers Identify New Cancer Targets, Engineer Promising Peptides, and Accelerate Next-Generation Drug Development
From
FN Media
Via
GlobeNewswire
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
Today 6:00 EST
Cooperation Between CLIA-Certified Cancer Diagnostics Laboratory and Canadian Tech-Bio Company Will Allow Artificial Intelligence Models to Interrogate World's Largest Primary Tumor Biobank DiaGen...
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
UPDATING ORIGINAL RELEASE DataMEDS AI Releases CEO Letter
November 16, 2026
Interim Co-CEO Lays Out Strategy Across Recent Investments Focused on the Synergies in the Company's Emerging Healthcare Ecosystem Ongoing turnaround focused on financial discipline, strategic...
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
DataMEDS AI Releases CEO Letter
November 16, 2026
Interim Co-CEO Lays Out Strategy Across Recent Investments Focused on the Synergies to in the Company's Emerging Healthcare Ecosystem Ongoing turnaround focused on financial discipline, strategic...
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
DataMEDS AI Reports 50% Sequential Revenue Growth in Third Quarter 2026 From Second Quarter 2026, Delivers Net Profit Per Share of $2.72 and Provides Business Update
November 13, 2026
Third quarter 2026 revenue of $2.7 million, up 50% from $1.8 million in the second quarter of 2026, primarily driven by growth in Corexa Pharmacy drug dispensing Launch of the Health Lives Here mobile...
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
DataMEDS AI Announces Corexa Pharmacy's First Commercial Sale of Compounded Peptides Under FDA Enforcement Discretion Policy
November 09, 2026
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
DataMEDS AI Signs MOU to Deploy Health Lives Here GLP-1 Patient Management Program with Florida-Based HMO
November 05, 2026
NFL Alumni Health to support HMO member engagement Relationship centers on improving member GLP-1 related outcomes through use of the Health Lives Here app and easy access to telehealth, pharmacy and...
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
DataMEDS AI Announces Termination of Second Amended and Restated Letter of Intent
November 03, 2026
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
DataMEDS AI Enters Into Agreement for Commercial Supply of Six Peptides Recommended by FDA Advisory Committee
November 02, 2026
Corexa Pharmacy to dispense compounded BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax in accordance with HHS' recently updated Enforcement Discretion Policy Bulk drug substance access facilitates 3PL...
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network
October 23, 2026
Being marketed to 6,500+ Corexa Health Pharmacy Network of independent pharmacies To be launched first at Corexa Pharmacy in Lakeland, FL retail location in Q4/2026 Program will aim to bring best...
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
DefenseNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT)Signs Letter of Intent to Acquire 19.9% Stake in DataMEDS AI (NASDAQ: MEDS)
October 22, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies
October 22, 2026
Proprietary IP Position Until At Least 2042 to Enable Consolidation of Infrastructure targeting market expected to grow from $9.6 billion in 2025 to $93.4 billion in 2035 Customer Acquisition Plan...
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
DataMeds Regains Compliance With NASDAQ Listing Standards
October 20, 2026
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
Premarket Movers Oct. 19: Disc Medicine Jumps 51.62%, Rubico Falls 33.84%
↗
October 19, 2026
Via
Chartmill
DataMeds Applauds FDA’s Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health’s Peptides Roadmap
October 16, 2026
DataMeds AI, Inc. (NASDAQ:MEDS) today applauded the issuance of a new policy proposal by the U.S. Food and Drug Administration (FDA) entitled “Interim Access Policy for Compounding Using Certain...
Via
B2i Digital
Topics
Artificial Intelligence
DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap
October 16, 2026
Corexa Health's three divisions - pharmacy, distribution, and tech & hub - positioned to serve the emerging compounded peptide market
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
DataMEDS Si Licenses U.S. Rights To Reboot Health AI’s Direct-To-Consumer GLP-1 Weight Management Platform
October 14, 2026
DataMeds AI, Inc. (NASDAQ:MEDS) today announced that it has entered into an exclusive license, revenue sharing and marketing agreement with REBOOT Health AI, Inc. (“REBOOT”) for Direct-to-Consumer...
Via
B2i Digital
Topics
Artificial Intelligence
Intellectual Property
DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform
October 14, 2026
Platform to be integrated into Health Lives Here app as a subscription offering
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division
October 13, 2026
DataMeds AI, Inc. (NASDAQ:MEDS) today announced that it has implemented cost control measures, primarily through reductions in corporate management positions, to focus the workforce spend on...
Via
B2i Digital
Topics
Artificial Intelligence
DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division
October 13, 2026
Leading Health IT Company has Implemented Cost Control Measures and Refocused Remaining Workforce Towards ChemoFx ® Commercialization with Hospital Systems, HMOs, GPOs and Cancer Centers
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
DataMEDS SI Announces Helomics Receives Medicaid Coverage Policy For Chemofx® Assay In Gynecologic Cancers
October 12, 2026
DataMeds AI, Inc. (NASDAQ:MEDS) today announced that its recently acquired CLIA-certified precision oncology laboratory subsidiary Helomics Corporation has received a Medicaid coverage determination in...
Via
B2i Digital
Topics
Artificial Intelligence
These stocks are moving in today's pre-market session
↗
October 12, 2026
Via
Chartmill
DataMEDS SI Announces Helomics Receives Medicaid Coverage Policy For Chemofx(R) Assay In Gynecologic Cancers
October 12, 2026
Humana adds ChemoFx ® to its Medicaid Pharmacogenomics Testing coverage policy
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
Top stock movements in today's session.
↗
October 08, 2026
Via
Chartmill
Datameds AI Files DBAs Datameds SI And Corexa Health SI And Reminds Shareholders Of Record As Of August 7, 2026 Of Dream Bowl Meme Coin I Payment
October 05, 2026
DataMeds AI, Inc. (NASDAQ:MEDS) today announced that it has filed DBAs for ‘DataMEDS SI’ and ‘Corexa Health SI’.
Via
B2i Digital
Topics
Artificial Intelligence
Datameds AI Files DBAs Datameds SI And Corexa Health SI And Reminds Shareholders Of Record As Of August 7, 2026 Of Dream Bowl Meme Coin I Payment
October 05, 2026
Healthcare IT Company and its Subsidiary Undertake Action Following US Government's Updated Nomenclature
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
DarkHorse CEO Details AI Infrastructure Strategy as DRK Targets Sub-50 MW Compute Opportunity
October 01, 2026
Via
AB Newswire
Topics
Artificial Intelligence
DataMeds AI’s Corexa Pharmacy Surpasses $1 Million In Monthly Revenue
October 01, 2026
DataMeds AI, Inc. (NASDAQ:MEDS), a healthcare company leveraging its Health IT and physical infrastructure together with its artificial intelligence platform EinsteinRx™ and smart contracts platform...
Via
B2i Digital
Topics
Artificial Intelligence
DataMeds AI's Corexa Pharmacy Surpasses $1 Million In Monthly Revenue
October 01, 2026
September 2026 revenue up more than 66 percent from July 2026 with expansion of retail customer base and Tollo Health pharmaceutical-adjunct product launches
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.